Transdermal FSH: Replacing Fertility Injections with a Self-Administered Patch

December 16, 2015

4P Therapeutics, a drug delivery company with expertise in novel transdermal technologies, announced the successful demonstration of preclinical proof-of-concept for a transdermal patch delivering follicle stimulating hormone. Read more

 
 

BioTuesdays features an interview with Founder & CEO Steve Damon.

February 24, 2015

Read more
 
 

Patients & Physicians Desire Transdermal, Topical, & Subcutaneous Delivery

July 2014

Drug Development and Delivery Magazine publishes 4P SPECIAL FEATURE. Read more
 
 

4P Therapeutics: Developing New Innovative Transdermal Products

June 2014

4P Therapeutics featured on the cover of Drug Development and Delivery Magazine. Read more
 
 

Novel Transdermal Delivery Systems for Treatment of Diabetes

May 2014

On Drug Delivery magazine publishes an article featuring Dr. Alan Smith, Vice President of Clinical, Regulatory, and Operations for 4P Therapeutics. Read more

 
 

4P Therapeutics Celebrates Headquarters Opening in Gwinnett County. Biotechnology company locates facility in the City of Peachtree Corners

June 28, 2013

(GWINNETT - METRO ATLANTA) Transdermal research and development company, 4P Therapeutics, will join Gwinnett Chamber Economic Development to celebrate the opening of its headquarters facility in the City of Peachtree Corners, Gwinnett County. Bringing an initial 12 new jobs to the County, the announcement represents $250,000 in capital investment for the community. Read more
 
 

4P Therapeutics Appoints Dr. Mark Prausnitz to Lead Their Scientific Advisory Board

May 15, 2013

4P Therapeutics, a drug delivery company with expertise in novel transdermal technologies, announced the appointment of Dr. Mark Prausnitz to lead the Company's Scientific Advisory Board.Read more

 
 

Addressing Challenges in Developing Drug Delivery Systems: Navigating Regulatory Requirements in the US

February 25, 2013

Q1 Productions, a leading educational provider for the pharmaceutical industry, conducted a webinar entitled "Addressing Challenges in Developing Drug Delivery Systems: Navigating Regulatory Requirements in the US" on Tuesday, February 25 at 1 pm EST. This live online meeting was presented by Alan Smith PhD., Vice President Clinical, Regulatory, and Operations at 4P Therapeutics, a private company focused on the research and development of novel drug delivery technologies and novel drug delivery-based therapeutics. Read more
 
 

4P Therapeutics Announces Partnership with Medicure for Development of Transdermal AGGRASTAT®

September 26, 2012

Atlanta, GA, September 26, 2012│4P Therapeutics, a drug delivery company with expertise in novel drug delivery technologies, announced a partnership with Medicure Inc. (TSXV:MPH, OTC:MCUJ.PK), for the development of a transdermal delivery formulation of its lead drug, AGGRASTAT® (tirofiban HCl). Read more

 
 

MEDICURE ANNOUNCES DEVELOPMENT OF NOVEL AGGRASTAT FORMULATION. Studies with 4P Therapeutics Demonstrate Ability to Deliver Tirofiban Transdermally

September 26, 2012

WINNIPEG, Manitoba, September 26, 2012│Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJ.PK), is pleased to announce the development of a transdermal delivery formulation of its lead drug, AGGRASTAT® (tirofiban HCl). The ability to administer a drug transdermally (i.e. through the skin) provides a convenient way to deliver a stable, therapeutic level of medication to the patient. Read more
 
 

Dow Jones Financial VentureWire Article

February 7, 2012

Former executives of Altea Therapeutics Corp., a venture-backed drug-delivery company that shut down late last year, have launched a start-up to pursue the same market in a less capital-intensive way. Read more